Drug intelligence / Profile preview

6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one

Development stage: Preclinical
Modality: Small Molecules

Overview

This compound is a small molecule belonging to the thieno[3,2-b]pyrrole[3,2-d]pyridazinone scaffold. It functions as an activator of the tumor-specific M2 isoform of pyruvate kinase (PKM2). The activation of PKM2 is a strategy being investigated in cancer therapeutics to revert cancer cells to a metabolic state characteristic of normal cells, thereby exploiting the distinct metabolic needs of cancer cells (Warburg effect).

Other names: 6-[(2-fluorophenyl)methyl]-2,4-dimethyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone

Targets

PKM2 (Pyruvate kinase M2 isoform)

Beyond the preview

Go deeper on 6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one.

Explore the full profile